12:00 AM
 | 
Oct 04, 1999
 |  BC Week In Review  |  Clinical News  |  Clinical Results

LymphoCide: Phase I/II

IMMU said that data from 36 patients in the company's 50-patient Phase I/II study showed a 67 percent objective response to lower...

Read the full 87 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >